Physician profile
Randy M Jay
NPI 1285707760
$5,468.67
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $702 · 2022: $2,047 · 2023: $1,671 · 2024: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Education: $19.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.19 |
| Education | $19.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,025.08 | 2021-2024 | Cimzia, Bimzelx |
| Abbvie INC. | $999.10 | 2021-2024 | |
| Amgen INC. | $996.36 | 2022-2024 | Enbrel, Prolia, Otezla |
| Janssen Biotech, INC. | $380.41 | 2021-2024 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $346.18 | 2022-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $205.05 | 2021-2022 | |
| Lilly USA, LLC | $172.03 | 2021-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.93 | 2022-2024 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $140.48 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $137.98 | 2022 | |
| Radius Health, INC. | $129.47 | 2022-2024 | Tymlos |
| Genzyme Corporation | $123.04 | 2021-2024 | |
| Pfizer INC. | $65.13 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $62.80 | 2023-2024 | Idacio, Tyenne |
| E.R. Squibb & Sons, L.L.C. | $61.40 | 2023-2024 | Orencia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $61.15 | 2023-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $59.47 | 2022-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $54.42 | 2021-2023 | Strensiq |
| Ferring Pharmaceuticals INC. | $52.24 | 2023-2024 | Euflexxa |
| Ultragenyx Pharmaceutical INC. | $34.72 | 2022 | |
| Octapharma USA, INC. | $34.28 | 2024 | Octagam Immune Globulin (Human) |
| Pharming Healthcare, INC. | $30.66 | 2023 | Ruconest |
| Horizon Therapeutics Plc | $28.23 | 2022 | |
| Mylan Institutional INC. | $27.24 | 2023 | Hulio |
| Sandoz INC. | $26.37 | 2024 | Hyrimoz |
| Celltrion USA INC. | $19.71 | 2023 | Yuflyma |
| Organon LLC | $13.84 | 2023 | Hadlima |
| Teva Pharmaceuticals USA, INC. | $12.90 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Jay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.